Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03891108 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03891108 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 60 participants.
The verdict
NCT03891108, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
Main Objective of this study is to compare the single intravenous (IV) infusion pharmacokinetics (PK) of BMS-986231 and its metabolites (BMT-284730, BMT-279554, and CAR-000463) following of up to 2 test formulations of BMS-986231 relative to the reference formulation.
Interventions
- DRUG BMS-986231 Formulation A
- DRUG BMS-986231 Formulation B
- DRUG BMS-986231 Formulation C
- DRUG BMS-986231 Formulation D
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2019-02-28 |
| Est. Completion | 2019-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03891108
The ClinicalTrials.gov registry entry for NCT03891108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BMS-986231 Formulation A is the first listed.
NCT03891108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03891108 about?
NCT03891108 is a clinical study titled "A Pharmacokinetics, Safety and Tolerability Study of Multiple Formulations of BMS-986231 in Healthy Participants". Main Objective of this study is to compare the single intravenous (IV) infusion pharmacokinetics (PK) of BMS-986231 and its metabolites (BMT-284730, BMT-279554, and CAR-000463) following of up to 2 test formulations of BMS-986231 relative to the reference formulation.
What is the current status of trial NCT03891108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2019-02-28. Estimated completion is 2019-07-29.
What interventions are being tested in trial NCT03891108?
The interventions under investigation include: BMS-986231 Formulation A (DRUG), BMS-986231 Formulation B (DRUG), BMS-986231 Formulation C (DRUG), BMS-986231 Formulation D (DRUG).
Who is sponsoring clinical trial NCT03891108?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.